These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 7904934)

  • 21. Class III antiarrhythmic agents: the next wave.
    Bauman JL
    Pharmacotherapy; 1997; 17(2 Pt 2):76S-83S; discussion 89S-91S. PubMed ID: 9085343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.
    Singh BN; Wadhani N
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Historical development of the concept of controlling cardiac arrhythmias by lengthening repolarization: particular reference to sotalol.
    Singh BN
    Am J Cardiol; 1990 Jan; 65(2):3A-11A; discussion 35A-36A. PubMed ID: 2403733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block.
    Milberg P; Ramtin S; Mönnig G; Osada N; Wasmer K; Breithardt G; Haverkamp W; Eckardt L
    J Cardiovasc Pharmacol; 2004 Sep; 44(3):278-86. PubMed ID: 15475823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiarrhythmic drugs and torsade de pointes.
    Lazzara R
    Eur Heart J; 1993 Nov; 14 Suppl H():88-92. PubMed ID: 8293758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent.
    Singh BN
    Am J Cardiol; 1996 Aug; 78(4A):41-53. PubMed ID: 8780328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Class III antiarrhythmic drugs.
    Singh BN; Ahmed R
    Curr Opin Cardiol; 1994 Jan; 9(1):12-22. PubMed ID: 8199363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol.
    MacNeil DJ
    Am J Cardiol; 1997 Oct; 80(8A):90G-98G. PubMed ID: 9354416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Class III antiarrhythmics in overdose. Presenting features and management principles.
    Leatham EW; Holt DW; McKenna WJ
    Drug Saf; 1993 Dec; 9(6):450-62. PubMed ID: 8129865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential effects of D-sotalol, quinidine, and amiodarone on dispersion of ventricular repolarization in the isolated rabbit heart.
    Zabel M; Hohnloser SH; Behrens S; Woosley RL; Franz MR
    J Cardiovasc Electrophysiol; 1997 Nov; 8(11):1239-45. PubMed ID: 9395166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiarrhythmic and antifibrillatory actions of the levo- and dextrorotatory isomers of sotalol.
    Lynch JJ; Wilber DJ; Montgomery DG; Hsieh TM; Patterson E; Lucchesi BR
    J Cardiovasc Pharmacol; 1984; 6(6):1132-41. PubMed ID: 6084771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A benefit-risk assessment of class III antiarrhythmic agents.
    Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
    Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative beta-blocking activities and electrophysiologic actions of racemic sotalol and its optical isomers in anesthetized dogs.
    Gomoll AW; Bartek MJ
    Eur J Pharmacol; 1986 Dec; 132(2-3):123-35. PubMed ID: 2880732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Class III antiarrhythmic drugs].
    Aiba T; Kamakura S
    Nihon Rinsho; 1996 Aug; 54(8):2125-31. PubMed ID: 8810787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of class III antiarrhythmic agents in maintaining sinus rhythm.
    Brachmann J
    Europace; 2000 Jul; 1 Suppl C():C10-5. PubMed ID: 11220519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.
    Riera AR; Uchida AH; Ferreira C; Ferreira Filho C; Schapachnik E; Dubner S; Zhang L; Moffa PJ
    Cardiol J; 2008; 15(3):209-19. PubMed ID: 18651412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiarrhythmic drugs: a reorientation in light of recent developments in the control of disorders of rhythm.
    Singh BN
    Am J Cardiol; 1998 Mar; 81(6A):3D-13D. PubMed ID: 9537217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Electrophysiologic profile of dronedarone on the ventricular level: beneficial effect on postrepolarization refractoriness in the presence of rapid phase 3 repolarization.
    Milberg P; Frommeyer G; Uphaus T; Kaiser D; Osada N; Breithardt G; Eckardt L
    J Cardiovasc Pharmacol; 2012 Jan; 59(1):92-100. PubMed ID: 21964157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of antiarrhythmic drug effects by beta-adrenergic sympathetic stimulation.
    Sager PT
    Am J Cardiol; 1998 Aug; 82(4A):20I-30I. PubMed ID: 9737651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sotalol: a breakthrough antiarrhythmic?
    Nappi JM; McCollam PL
    Ann Pharmacother; 1993 Nov; 27(11):1359-68. PubMed ID: 8286812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.